1. MARKETS
  2. SECTOR : PHARMA & BIOTECH
  3. INDUSTRY : MAJOR PHARMACEUTICALS
  4. ATLANTIC INTERNATIONAL CORP.
Atlantic International Corp.
XNAS: ATLN
Download real time
1.25 -0.08 (-6.02%)
76.19% Fall from 52W High
208.0K
XNAS Volume
High vol.+loss this week

XNAS 05 May, 2026 2:50 PM (EDT)

Watchlist

Portfolio

Alert
Board Meeting
The next board meeting for Atlantic Intl Corp is on 14 May 2026 for the purpose of Atlantic International Corp First Quarter Earnings Results for 2026 See details


Insider Trading disclosures for Atlantic Intl Corp

The latest disclosure was made by David Pfeffer in Atlantic Intl Corp where a trade of 161,290 Restricted Stock Units done was reported to US exchanges on March 12, 2026.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name Client Category Action Reported to Exchange Quantity Post Transaction Holding Traded % Avg. Price Value Security Type
David Pfeffer Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 12 Mar 2026 161,290 0 - - Restricted Stock Units
David Pfeffer Director Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. 12 Mar 2026 161,290 162,820 - 0 Common Stock
Matthew Evelt Chief Operating Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 05 Jan 2026 100,000 1,100,000 - - Incentive Stock Options
Michael Tenore General Counsel Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jan 2026 125,000 125,000 - - Incentive Stock Options
Michael Tenore General Counsel Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.33 per share. 01 Jan 2026 1,202,901 1,843,725 - 1.3 1,599,858 Common Stock, $.00001 par value
Michael Tenore General Counsel Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.33 per share. 01 Jan 2026 264,860 1,266,554 - 1.3 352,264 Common Stock, $.00001 par value
Jeffrey M. Jagid Director, Chief Executive Officer, Ten Percent Owner Grant, award, or other acquisition of securities at price $ 0.00 per share. 01 Jan 2026 1,000,000 1,000,000 - - Incentive Stock Option
Jeffrey M. Jagid Director, Chief Executive Officer, Ten Percent Owner Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.33 per share. 01 Jan 2026 5,551,223 8,221,025 - 1.3 7,383,127 Common Stock, $.00001 par value
Christopher Broderick Chief Financial Officer Sale or transfer of securities back to the company at price $ 0.00 per share. 15 Aug 2025 577,171 0 - - Restricted Stock Units
Michael Tenore General Counsel Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Aug 2025 264,860 842,031 - - Restricted Stock Award
Jeffrey M. Jagid Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 11 Aug 2025 1,000,000 3,885,856 - - Restricted Stock Award
Jeffrey M. Jagid Director, Chief Executive Officer Gift of securities by or to the insider at price $ 0.00 per share. 11 Aug 2025 400,000 3,335,169 - 0.0 40 Common Stock, $.00001 par value
Jeffrey M. Jagid Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Jun 2025 2,885,856 2,885,856 - - Restricted Stock Units
Michael Tenore General Counsel Purchase of securities on an exchange or from another person at price $ 0.00 per share. 23 Jun 2025 577,171 1,001,634 - 0.0 58 Common Stock, $.0001 par value
Michael Tenore General Counsel Grant, award, or other acquisition of securities at price $ 0.00 per share. 23 Jun 2025 577,171 577,171 - - Restricted Stock Units
Christopher Broderick Chief Financial Officer 23 Jun 2025 577,171 2,004,237 - 0.0 58 Common Stock, $.0001 par value
Christopher Broderick Chief Financial Officer 23 Jun 2025 577,171 577,171 - - Restricted Stock Units
Jeffrey M. Jagid Director, Chief Executive Officer Purchase of securities on an exchange or from another person at price $ 0.00 per share. 23 Jun 2025 2,885,856 3,735,169 - 0.0 289 Common Stock, $.0001 par value
Matthew Evelt Chief Operating Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jun 2025 1,000,000 1,000,000 - - Incentive Stock Options
Michael Tenore General Counsel Purchase of securities on an exchange or from another person at price $ 0.00 per share. 07 Jan 2025 577,171 1,578,865 - 0.0 58 Common Stock, $.00001 par value
Michael Tenore General Counsel Grant, award, or other acquisition of securities at price $ 0.00 per share. 07 Jan 2025 577,171 577,171 - - Restricted Stock Units
Christopher Broderick Chief Financial Officer 07 Jan 2025 577,171 2,581,408 - 0.0 58 Common Stock, $.00001 par value
Christopher Broderick Chief Financial Officer 07 Jan 2025 577,171 577,171 - - Restricted Stock Units
Jeffrey M. Jagid Director, Chief Executive Officer Purchase of securities on an exchange or from another person at price $ 0.00 per share. 02 Jan 2025 2,885,856 6,621,025 - 0.0 289 Common Stock, $.00001 par value
Jeffrey M. Jagid Director, Chief Executive Officer Grant, award, or other acquisition of securities at price $ 0.00 per share. 02 Jan 2025 2,885,856 2,885,856 - - Restricted Stock Units
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc  
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges
View All The Insider Trades disclosures
Screeners based on Insider Trading and SAST parameters